| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537581 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US10806697 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11497709 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11351182 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US10835487 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11241445 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US9289382 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11246875 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11304959 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US10668082 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
| US10888516 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US11123283 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US10471072 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
| US11116717 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US11065197 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US10568891 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
| US10398708 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(9 years from now) | |
| US9180091 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Dec, 2033
(9 years from now) | |
| US10258630 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(9 years from now) | |
| US11266661 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Feb, 2034
(9 years from now) | |
Imvexxy is owned by Mayne Pharma.
Imvexxy contains Estradiol.
Imvexxy has a total of 20 drug patents out of which 0 drug patents have expired.
Imvexxy was authorised for market use on 29 May, 2018.
Imvexxy is available in insert;vaginal dosage forms.
Imvexxy can be used as treatment of a symptom of vulvar and vaginal atrophy, treatment of dyspareunia, treatment of moderate to severe dyspareunia.
The generics of Imvexxy are possible to be released after 02 February, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2021 |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of a symptom of vulvar and vaginal atrophy; Treatment of dyspareunia; Treatment of moderate to severe dyspareunia
Dosage: INSERT;VAGINAL
IMVEXXY family patents
